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bursed in Australia for the treatment of patients with genotype 1
hepatitis C virus (HCV) infection in combination with pegylated
interferon and ribavirin (PR). Objectives: To assess the cost-
effectiveness of telaprevir plus PR compared with PR alone in 1)
previously untreated patients and 2) patients who had received
treatment with PR earlier. Methods: Sustained virological response
rates and average treatment durations of telaprevir and PR (given with
or without telaprevir) were taken from the telaprevir ADVANCE and
REALIZE clinical trials but were modiﬁed to take account of differ-
ences in prescribing rules between the trials and Australian clinical
practice. The probability of transitioning between Markov disease
states was based on data from the Australian Kirby Institute where
possible and supplemented using data from the published literature.
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ndence to: Emma Warren, Hera Consulting Austraquestionnaire data collected in the ADVANCE and REALIZE trials were
used to represent the utility during HCV treatment. Utility values for
Markov health states were taken from the published literature. Unit costs
(2014 AU $) were taken from Australian sources. Results: In treatment-
naive patients, the discounted cost per life-years gained was AU $37,706
and the discounted cost per quality-adjusted life-year was AU $19,283. In
treatment-experienced patients, the discounted cost per life-year gained
was AU $23,855 and the discounted cost per quality-adjusted life-year was
AU $14,948. Conclusion: Telaprevir plus PR in the Australian setting is
cost-effective when compared with PR alone in patients infected with
genotype 1 HCV.
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Chronic hepatitis C virus (HCV) infection is a leading cause of
chronic liver disease in Australia, representing a substantial
burden in terms of morbidity, mortality, and costs. In 2012, the
number of people living with chronic HCV infection in Australia
was estimated to be 231,500 [1] and approximately 55% of these
are infected with genotype 1 [2]. The virus is transmitted by
blood-to-blood contact and reproduces within hepatic cells. Over
time, the endless cycle of viral reproduction results in signiﬁcant
damage to the patient’s liver. Unlike hepatitis A or B, there is no
vaccine for HCV. Successful treatment, however, can result in a
cure (sustained virological response [SVR]) by elimination of
the virus.
Telaprevir (Incivo), a selective HCV NS3/4A serine protease
inhibitor, has been reimbursed through the Pharmaceutical
Beneﬁts Scheme (PBS) since April 2013. Clinical trials [3,4] have
demonstrated that telaprevir in combination with pegylated
interferon and ribavirin (PR) is superior to PR alone (the previous
standard of care) in patients with genotype 1 chronic HCV
infection (i.e., telaprevir plus PR generates signiﬁcantly more
SVRs than does PR alone). Furthermore, the use of telaprevir plusPR in a previously untreated patient can reduce the duration of
coadministered PR therapy. This is because patients without
cirrhosis on telaprevir who achieve an extended rapid viral
response (deﬁned as achieving undetectable HCV RNA levels at
weeks 4 and 12) can reduce their duration of PR therapy to 24
weeks instead of requiring a 48-week course.
There are four recently published economic evaluations of
telaprevir, three of which are performed either in the treatment-
naive setting [5] or in the treatment-experienced setting [6,7]. Only
one previous evaluation [8] has used the same model structure to
estimate the cost-effectiveness of telaprevir in both treatment
settings. The objective of our study was to calculate the incre-
mental cost-effectiveness ratio (ICER) of telaprevir plus PR com-
pared with PR alone in an Australian setting in both patients who
are naive to treatment and those who have previously failed
treatment with PR (treatment-experienced patients). As a result,
our study not only uses the same model to estimate the cost-
effectiveness of telaprevir in both treatment settings but also
incorporates the revised categorization of SVR accepted by the
Australian regulatory authority (Therapeutic Goods Administra-
tion), and the stopping rules for telaprevir and PR that are
consistent with the PBS reimbursement criteria for these therapies.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
lia Pty Ltd., 515 Darling Street, Balmain, NSW 2041, Australia.
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Model Structure
The model has two components (Fig. 1). The ﬁrst year of the
model (in which patients are receiving HCV treatment) is modeled
as a trial-based decision tree. After receiving antiviral treatment
in the setting of mild (no or minimal), moderate (portal or
bridging), or severe (compensated cirrhosis) ﬁbrosis, patients can
either achieve an SVR or not. In the second year, depending on
their SVR status after treatment, patients enter the long-term
Markov structure that was used to simulate the natural history of
HCV infection over a 60-year (lifetime) time horizon with annualFig. 1 – Markov model structure. Every year, patients can move
probability. Note. Age standardised, all cause mortality was also
decompensated cirrhosis and HCC, but has been excluded from
hepatitis C virus; SVR, sustained virological response.Markov cycles. Similar to other published economic models of
telaprevir [5,7], the following health states were incorporated into
the Markov model: SVR after mild or moderate ﬁbrosis, SVR after
cirrhotic disease, mild HCV (no SVR), moderate HCV (no SVR),
compensated cirrhosis, decompensated cirrhosis, hepatocellular
carcinoma (HCC), liver transplant (ﬁrst year), post–liver transplant
(subsequent years), and death (Fig. 1). As a result of the improved
SVR rate, fewer patients treated with telaprevir plus PR experi-
enced disease progression to liver failure, HCC, or liver transplant
than did patients treated with PR alone, with each of these events
associated with an increased probability of death. At a request of
the Australian Pharmaceutical Beneﬁts Advisory Committee, the
model assumes that 1.8% of the patients with an SVR are
reinfected with HCV at 2 years (based on a study of 395 subjectsbetween heath states according to a deﬁned transition
included from the more severe health states such as
this diagram for clarity. HCC, hepatocellular carcinoma; HCV,
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state that they occupied before achieving their SVR (i.e., mild HCV,
moderate HCV, or cirrhosis) because retreatment is not incorpo-
rated and experience the same degree of disease progression as
do those who did not achieve an SVR. Costs are analyzed using an
Australian government perspective (2014 prices) and include drug
costs, patient monitoring costs, costs associated with treating
telaprevir-induced adverse events, and savings associated with
avoided future hepatic events. Future years’ costs and quality-
adjusted life-years (QALYs) were discounted by 5% in accordance
with Australian guidelines. The model was developed in Microsoft
Excel (Microsoft Corporation, Redmond, WA).
Patient Cohort and Demographic Characteristics
The model was constructed to compare the cost-effectiveness of
telaprevir in two populations: 1) previously untreated patients
(treatment naive) and 2) patients who had received treatment
with PR earlier (treatment experienced). Consistent with PBS
reimbursement of telaprevir in Australia, patients with HCV
infection with mild ﬁbrosis, moderate ﬁbrosis, or compensated
cirrhosis are eligible for telaprevir treatment.
The patient population in the treatment-naive model is
based on the ADVANCE study (age 49 years, 58.7% men, 38.8%
with mild HCV, 55.4% with moderate HCV, and 5.8% with com-
pensated cirrhosis at baseline) [3]. The patient population in the
treatment-experienced model is based on the REALIZE study [4]
(age 51 years, 68.6% men, 21.6% with mild HCV, 52.8% with
moderate HCV, and 25.6% with compensated cirrhosis at baseline),
in which all subjects had failed at least one course of PR therapy.
The ADVANCE and REALIZE trials are broadly representative of
Australian patients with genotype 1 chronic HCV infection.
Comparative Efﬁcacy of Telaprevir
SVR rates (deﬁned as undetectable HCV RNA levels 24 weeks after
the completion of therapy) used in the model are presented in
Table 1. The SVR rates were calculated from the individual patient
data from the ADVANCE [3] and REALIZE [4] studies. The revised
categorization of SVR (used in both the Therapeutic Goods Admin-
istration–approved Australian Product Informations for telaprevir
[10] and boceprevir [11]), however, differs slightly from the meth-
odology used in the ADVANCE [3] and REALIZE [4] publications,
with regard to the handling of missing data 24 weeks after the
completion of therapy, and use of a HCV RNA quantiﬁcation level
of less than 25 IU/mL, as accepted by regulatory authorities.
Disease Progression
During each annual Markov cycle, patients remain in their
current health state, progress to the next more severe health
state, or die. Markov transition probabilities were taken fromTable 1 – SVR rates used in the model.
Baseline ﬁbrosis status Treatment-naive mode
Telaprevir þ PR
Mild HCV 85.1% (114 of 134) 48.3%
Moderate HCV 75.0% (156 of 208) 45.1%
Cirrhosis 71.4% (15 of 21) 38.1%
Note. The total number of SVRs in the model is identical to the TGA-appro
HCV consists of no or minimal ﬁbrosis and moderate HCV consists of p
HCV, hepatitis C virus; PR, pegylated interferon plus ribavirin; SVR, sustAustralian-speciﬁc sources where possible. Where Australian-
speciﬁc data were not available, transition probabilities were
taken from the published literature [1,12–20]. The probability of
receiving a liver transplant is country-speciﬁc. The annual prob-
ability of receiving a liver transplant for patients with HCC has
been calculated by dividing the number of liver transplants due
to HCC (12 transplants) by the total number of patients with HCC
in the same year (132 patients) [1]. The annual probability of a
liver transplant in patients with decompensated cirrhosis has
been taken from the Australian budget impact model conducted
by the Kirby Institute [16]. The annual probability of death due to
HCC has been estimated using the 5-year survival rates reported
in New South Wales and Victoria [18,19], the two most populous
states in Australia. An average of the 5-year survival rates
reported in New South Wales and Victoria (15.2%) has been
converted into an annual probability (0.314) using the formula
P ¼ 1 – expr, where P is the annual probability and r is the annual
rate of death. Data from the Australian and New Zealand Liver
Transplant Registry have been used to determine the probability
of death after transplant, which is signiﬁcantly greater in the ﬁrst
year after the transplant than in subsequent years. Australian
data suggest that posttransplant survival rates are 89% and 71%
at 1 and 10 years, respectively [17]. Thus, the estimated annual
probability of death during the ﬁrst year after transplant is 0.110.
The estimated annual probability of death during subsequent
years is 0.022.
Table 2 presents the Markov transition probabilities used in the
model. Not all the published economic models permit treatment of
patients with HCV infection with cirrhosis (i.e., the treated pop-
ulation is restricted to those with mild or moderate HCV infection).
However, in many of the published models that do include
patients with cirrhosis in the treated population [21–23], patients
achieving an SVR are considered to be “cured” of their virus
irrespective of their ﬁbrosis status before treatment. Some of the
more recent evaluations [7,24], however, incorporate disease pro-
gression to HCC for patients with cirrhosis who achieve an SVR.
Consistent with this more recent methodology, this telaprevir
economic model assumes that patients with cirrhosis who achieve
an SVR after treatment experience some degree of disease pro-
gression to HCC (Table 2). The probability of developing HCC in
patients who do not achieve an SVR is taken from a longitudinal
study of 384 patients [15]. The odds ratio of progression to HCC in
patients achieving an SVR compared with those not achieving an
SVR is 0.4 [20]. Therefore, the annual probability of developing HCC
in patients with cirrhosis who achieved an SVR is 0.006 (¼ 0.015 
0.4). Furthermore, the evaluation performed by Chhatwal et al. [24]
also incorporates progression to decompensated cirrhosis for
patients with cirrhosis who achieved an SVR. Consistent with
most of the published models and Australian clinical advice, the
base case of this telaprevir model assumes no progression to
decompensated cirrhosis in those who achieved an SVR. Thisl Treatment-experienced model
PR Telaprevir þ PR PR
(71 of 147) 72.5% (37 of 51) 20.0% (7 of 35)
(87 of 193) 72.0% (103 of 143) 16.4% (11 of 67)
(8 of 21) 47.2% (34 of 72) 10.0% (3 of 30)
ved Australian Product Information [10]. However, in the model, mild
ortal or bridging ﬁbrosis.
ained virological response; TGA, Therapeutic Goods Administration.
Table 2 – Transition probabilities used to model disease progression.
Initial health state Resulting health state Transition probabilities Source
Mild HCV Moderate HCV 0.041 [12–14]
Moderate HCV Cirrhosis 0.073 [12–14]
Cirrhosis Decompensated cirrhosis 0.039 [15]
HCC 0.015 [15]
Decompensated cirrhosis HCC 0.015 [15]
Liver transplant 0.033 [16]
Liver-related death 0.129 [15]
HCC Liver transplant 0.091 [1]
Liver-related death 0.314 [18,19]
Liver transplant ﬁrst year Liver-related death 0.110 [17]
Liver transplant subsequent years Liver-related death 0.022 [17]
Cirrhotic SVR HCC 0.006 [20] (Appendix 4)
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SVR, sustained virological response.
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sex-standardized all-cause mortality rates were obtained from
Australian life tables [25].
Costs of Treatment
Table 3 presents the unit costs used in the model. The cost of 6-
week treatment with telaprevir in Australia is AU $14,866 [26].
Consistent with the PBS reimbursement criterion for telaprevir,
the model assumed that only those patients whose plasma HCV
RNA level is less than 1000 IU/mL at the week-4 assessment
receive the full 12-week course of telaprevir [26]. The model also
assumed that patients who discontinued telaprevir treatment in
the ADVANCE [3] and REALIZE [4] trials because of adverse events
were dispensed 6 weeks of telaprevir treatment (because one
prescription provides patients with 6 weeks of supply). The
average duration of telaprevir therapy is estimated to be 11.3
weeks in the treatment-naive setting and 11.1 weeks in the
treatment-experienced setting.
The cost of 8-week treatment with PR in Australia is AU $3406
[26]. The duration (and hence cost) of PR treatment in both arms
of the model is consistent with the PBS reimbursement criteria
for PR [26]. The model assumed that patients who discontinued
PR because of adverse events [3,4] were dispensed 8 weeks of PR
treatment (because one prescription provides 8 weeks of supply).
In the treatment-naive setting, the average duration of PR treat-
ment is estimated to be 27.6 weeks when coadministered with
telaprevir and 39.9 weeks when administered alone. In this
setting, the average duration of PR treatment is shorter when
administered with telaprevir. This is because treatment-naive
patients without cirrhosis on telaprevir who achieve an extended
rapid viral response can reduce their duration of PR therapy to 24
weeks instead of requiring a 48-week course. Approximately 60%
of the patients who receive telaprevir plus PR in the treatment-
naive setting would be able to reduce their duration of PR to 24
weeks. In the treatment-experienced setting, the average dura-
tion of PR when given with telaprevir is 32.3 weeks and only 21.5
weeks when given alone. In this setting, the average duration of
PR treatment is shorter when administered without telaprevir
because patients are discontinuing PR therapy because of lack of
effect.Costs of Monitoring
As given in Table 3, all unit costs for pathology, clinician visits,
and HCV RNA level monitoring are taken from the Australian
Medicare Beneﬁts Schedule [27]. It is assumed that patients
underwent pathology screening (full blood cell count, liverfunction, prothrombin time, and thyroid function) before the
commencement of antiviral treatment. Patients receiving telap-
revir plus PR are assumed to visit the specialist at baseline, at
weeks 4, 6, and 12, and for an assessment of SVR status 24 weeks
after completing treatment. Patients treated with PR alone
undergo a similar schedule of physician visits but omit visits at
weeks 4 and 6. Nurse visits for both treatment arms occur at
weeks 4, 12, and 24 (if the patient is still on treatment) and at end
of treatment. For patients on telaprevir plus PR, quantitative HCV
RNA assays are conducted at baseline and week 4 (to determine
whether the patient’s plasma HCV RNA level is o1000 IU/mL),
and qualitative HCV RNA assays are conducted at week 12, end of
treatment (if after week 12), and at assessment of SVR status (24
weeks after the last dose of treatment). Patients treated with PR
alone undergo a similar schedule of HCV RNA testing; however,
the quantitative assay is conducted at week 12 (instead of week 4)
to determine whether the patient fulﬁls the criteria for continu-
ing PBS-subsidized PR treatment.
Costs Associated with Telaprevir-Induced Adverse Events
The model incorporated the cost of telaprevir-induced anemia
and rash. The incidence of these adverse events was taken from
the ADVANCE and REALIZE trials [3,4]. The telaprevir Product
Information recommends reducing the ribavirin dose in patients
experiencing anemia [10]. Consistent with Blazquez-Perez
and San Miguel [5], patients experiencing anemia were assumed
to incur the cost of two visits to their specialist and two blood
cell count tests. All patients experiencing rash incurred the
cost of one GP visit and betamethasone steroid cream. In ad-
dition, patients experiencing rash at a grade 3 severity level or
above were assumed to visit their specialist and patients whose
rash was graded as serious incurred the cost of treatment in
hospital [28].
Costs Associated with HCV
With respect to the annual cost of each Markov health state, the
same methodology was applied as was used in a previous
Australian economic model [29]. In the Shiell et al. [29] model,
the resources used in each health state were based on clinical
protocols as speciﬁed by the National Health and Medical
Research Council and the clinical opinion of one of the authors
(Director of Gastroenterology and Hepatology at The Canberra
Hospital). The type and quantity of resource used in each health
state have been taken from Shiell et al. [29] (because more recent
information is not available). The unit cost for these resources
was updated using 2014 cost data from the Medicare Beneﬁts
Schedule and Australian national diagnosis related groups for
Table 4 – Utility values and cost of each
Markov state.
Health state Utility
[33]
Annual cost
(AU $)
SVR after treatment at mild stage 0.82 159.55
SVR after treatment at moderate
stage
0.72 159.55
SVR after treatment at cirrhotic
stage
0.66* 270.85
Mild HCV 0.77 281.40
Moderate HCV 0.66 281.40
Compensated cirrhosis 0.55 715.15
Decompensated cirrhosis 0.45 13,806.59
HCC 0.45 17,567.22
Liver transplant 0.45 145,565.00
Post–liver transplant 0.67 13,806.59
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SVR,
sustained virological response.
* Assumed equivalent to moderate HCV.
Table 3 – Unit costs.
Resource use Cost
(AU $)
Source
Telaprevir drug costs
(6-wk therapy)
14,865.72
PBS, Section 100 public
hospital cost [26]
PR drug costs (8-wk
therapy)
3,406.36
PBS, Section 100 public
hospital cost [26]
Betamethasone cream 13.35 PBS [26]
Lactulose 3.34 g/5 mL,
500 mL
10.57 PBS [26]
GP visit 36.30 MBS Item number 23 [27]
Specialist visit
(initial)
85.55 MBS Item number 104 [27]
Specialist visit
(subsequent)
43.00 MBS Item number 105 [27]
Nurse visit (o20 min) 20.95 MBS Item number 82205 [27]
Nurse visit (>20 min) 39.75 MBS Item number 82210 [27]
Clinical psychologist 99.75 MBS Item number 80000 [27]
HCV RNA quantative
assay
180.25 MBS Item number 69488 [27]
HCV RNA qualitative
assay
92.20 MBS Item number 69445 [27]
Unit cost of
hospitalization for
rash
10,882.00
AR-DRG for major skin
disorders (J68A) [28]
Full blood cell count 16.95 MBS Item number 65070 [27]
Liver function tests 17.70 MBS Item number 66512 [27]
Alfa fetoprotein tests 24.35 MBS Item number 66650 [27]
Ultrasound 111.30 MBS Item number 55036 [27]
Liver transplant 145,565.00
AR-DRG for liver transplant
(A01Z) [28]
Creatinine tests 17.70 MBS Item number 66512 [27]
Prothrombin time 13.70 MBS Item number 65120 [27]
Paracentesis 52.20 MBS Item number 30406 [27]
Thyroid function tests 34.80 MBS Item number 66719 [27]
Diagnostic endoscopy
(þ anesthetic) 320.25 MBS Item number 30475 [27]
AR-DRG, Australian reﬁned diagnostic related group; GP, general
practice; HCV, hepatitis C virus; MBS, Medicare Beneﬁts Scheme;
PBS, Pharmaceutical Beneﬁts Scheme; PR, pegylated interferon
plus ribavirin; RNA, ribonucleic acid.
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health state is given in Table 4.
Quality of Life
A utility value was associated with each health state to assess
quality of life. Utility scores for the ﬁrst year of the model (in
which patients are receiving HCV treatment) are taken directly
from the three-level EuroQol ﬁve-dimensional questionnaire
data collected in the ADVANCE and REALIZE studies [3,4]
(because this takes into account the utility gains associated
with a reduced duration of PR therapy in patients who achieve
an extended rapid viral response, and the disutility associated
with adverse events), using the UK algorithm [30] to assign an
index value to each EuroQol ﬁve-dimensional questionnaire
health state. During the ﬁrst year, treatment-naive patients
receiving telaprevir plus PR have a mean utility of 0.797 and
patients treated with PR alone have a mean utility of 0.782 [31].
In the treatment-experienced setting, patients receiving telap-
revir plus PR have a mean utility of 0.695 and patients treated
with PR alone have a mean utility of 0.710 [32]. Given that PR
therapy is associated with psychological adverse events (suchas insomnia, depression, and anxiety), it is reasonable that
shortening the duration of PR treatment in treatment-naive
patients results in a small utility gain.
Utility values for Markov health states have been taken from
Wright et al. [33] because these were obtained via the EuroQol
ﬁve-dimensional questionnaire (which was also used in the
telaprevir studies [3,4]). The model reported in Wright et al. [33]
was constructed on behalf of the National Institute for Health
and Care Excellence in the United Kingdom. Patients infected
with genotype 1 chronic HCV infection live a reduced quality of
life, commonly experiencing fatigue, irritability, depression, loss
of appetite, abdominal pain, muscle aches, and fever as well as
discrimination and stigma about their disease. Therefore, it
follows that utility values in patients who achieve an SVR are
typically higher than in those who have not achieved an SVR.
Table 4 presents the utility value for each health state in the
Markov model.Model Validation
Internal validity was assessed through routine “debugging” (i.e.,
setting identical SVR rates for both treatment arms, eliminating
disease-speciﬁc mortality, and setting utility weights to 1). With
regard to external validation, we projected the incidence of liver-
related complications (compensated cirrhosis, decompensated
cirrhosis, and HCC) for comparison with other studies. The
treatment-naive model predicted a 20-year risk of 28% of devel-
oping compensated cirrhosis in the PR-alone arm. This result is
slightly higher than the 25% risk for the PR treatment arm
reported in Siebert et al. [34], the overestimation in our model
most likely due to the reincorporation of patients with SVR who
become reinfected. The telaprevir model by Blazquez-Perez and
San Miguel [5] estimated that 21% of the patients have progressed
to cirrhosis at 20 years. For comparison, if the baseline ﬁbrosis
status is amended to be the same as Blazquez-Perez and San
Miguel [5] (mild 80%, moderate 14%, cirrhosis 6%), the Markov
model predicted a 20-year risk of 17% of developing compensated
cirrhosis, highlighting the importance of sensitivity analyses
around the baseline ﬁbrosis status of patients. Our base-case
model, however, predicted 20-year risks for decompensated
cirrhosis (10% in our model vs. 11% in Siebert et al. [34]) and
HCC (4.5% in our model vs. 4.7% in Siebert et al. [34]) that are
consistent with other studies [34].
Table 5 – Incremental cost-effectiveness ratios.
Treatment group Discounted costs
(AU $)
Discounted LY Discounted QALYs ICER ($/LYG) ICUR ($/QALY)
Treatment-naive population
PR alone 31,547 15.64 11.02 – –
Telaprevir plus PR 47,322 16.06 11.84 37,706 19,283
Treatment-experienced population
PR alone 36,448 14.31 9.19 – –
Telaprevir plus PR 55,537 15.11 10.46 23,855 14,948
Note. ICER and ICUR are incremental to PR alone.
ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utility ratio; LY, life-year; LYG, life-years gained; PR, pegylated interferon
plus ribavirin; QALY, quality-adjusted life-year.
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which relate to the severity of the disease (mild ﬁbrosis,
moderate ﬁbrosis, and compensated cirrhosis). The published
model constructed by the Australian Kirby Institute [16] has ﬁve
Markov health states relating to the severity of the HCV
infection (F0, F1, F2, F3, and cirrhosis). To validate the results
generated in the telaprevir model, an adaptation was performed
in which our model was adapted to incorporate ﬁve ﬁbrosis
health states. The telaprevir three-state ﬁbrosis model gener-
ated similar estimates of incidence of cirrhosis as did the model
using ﬁve ﬁbrosis states. Thus, the telaprevir economic model is
consistent with the Kirby Institute model at predicting down-
stream health states.
Sensitivity Analysis
Univariate sensitivity analyses were performed on parameter
values to determine the impact on ICERs, including discount
rate (0% and 3.5% for both costs and beneﬁts), ﬁbrosis status of
patients at baseline, SVR rates, transition probabilities, utility
values, health state costs, and background mortality. Consistent
with a small number of published evaluations [20,24], we
examined the impact of assuming that patients with cirrhosis
who achieve an SVR experience progression to decompensated
cirrhosis (in addition to HCC), with an annual transition prob-
ability of 0.0125 [20]. Several of the most recently published
evaluations have introduced higher non–liver-related mortality
in patients with chronic HCV infection compared with the
general population [5,8,35]. We conducted a sensitivity in which
age- and sex-standardized all-cause mortality rates for the
entire modeled population were 2.34 times [36] that obtained
from the Australian life tables (i.e., patients with SVR also incur
the increased risk of non–liver-related mortality). In addition,
because probabilistic sensitivity analysis is not required for
reimbursement in Australia, multivariate sensitivity analyses
were conducted combining the variables shown to be sensitive
in the univariate analyses.Results
Base-Case Analysis
Using a cohort of 1000 patients in the treatment-naive setting,
108 incident cases of decompensated cirrhosis, 46 incident cases
of HCC, and 26 liver transplants will be avoided over the lifetime
horizon of the model. Discounted costs, discounted outcomes,
and incremental cost-effectiveness results are presented in
Table 5. In both the treatment-naive setting and the treatment-
experienced setting, the discounted incremental cost-utility ratio
is below AU $20,000/QALY (AU $19,283/QALY in treatment-naivepatients and AU $14,948/QALY in treatment-experienced
patients). Even though there is no ﬁxed threshold for cost-
effectiveness in Australia, technologies with a cost/QALY of this
magnitude are typically considered to be cost-effective [37].
Sensitivity Analyses
Sensitivity analyses show the impact of different variables on
the ICER. We conducted extensive univariate analyses. Further-
more, multivariate sensitivity analyses were conducted, com-
bining the variables shown to be sensitive in the univariate
analyses. Table 6 presents the results of the sensitivity analysis.
The model was most sensitive to the annual rates of disease
progression (i.e., the Markov transition probabilities), the pro-
portion of patients achieving an SVR, and the utility score given
to patients who achieved an SVR. The results from the sensi-
tivity analyses, however, support the cost-effectiveness of
telaprevir, with the ICER in the treatment-naive setting varying
from AU $1,319 to AU $44,250 per QALY. In the treatment-
experienced setting, the ICER ranged from a situation in which
telaprevir plus PR dominated PR alone (discount rate is 0%) to a
cost/QALY of AU $34,589 (Markov transition probabilities were
the lowest values found in the literature). The range of ICERs in
both treatment settings were within the acceptable cost-
effectiveness range in Australia.Discussion
Treatment with telaprevir signiﬁcantly improves the likelihood
of achieving an SVR [3,4]. The results of this study demonstrate
that treatment with telaprevir plus PR is expected to result in
fewer incident cases of decompensated cirrhosis, HCC, and liver
transplants, consequently reducing future health state costs and
improving survival. The cost-utility analysis shows that telap-
revir plus PR is cost-effective in both the treatment-naive setting
and the treatment-experienced setting, with the base-case
discounted ICER below AU $20,000/QALY. The sensitivity anal-
ysis shows that the results are sensitive to the SVR rates, the
Markov transition probabilities, and the utility weights for
patients achieving an SVR. The results, however, support the
cost-effectiveness of telaprevir, with the incremental cost/QALY
below AU $45,000 in all sensitivity analyses in both treatment
settings. Given that a probabilistic sensitivity analysis has not
been performed, the full extent of the uncertainty surrounding
the cost-effectiveness of telaprevir in Australia remains
unknown.
As previously discussed, there are four recently published
economic evaluations of telaprevir [5–8]. Only one previous
evaluation [8] used the same model structure to estimate the
cost-effectiveness of telaprevir in both treatment settings.
Table 6 – Sensitivity analyses (discounted cost/QALY).
Variable Treatment naive Treatment experienced
Values used in sensitivity
analysis
ICER
($)
Values used in sensitivity
analysis
ICER ($)
Subgroup analysis based on ﬁbrosis status at baseline
Mild ﬁbrosis 26,070 28,736
Moderate ﬁbrosis 17,047 11,984
Cirrhosis 6,837 13,304
Univariate analyses
Fibrosis status SVR for
telaprevir
þ PR (%)
Fibrosis
status
SVR for
telaprevir
þ PR (%)
Lower 95% CI around incremental
SVR rates*
Mild 75.0 33,815 Mild 54.5 25,128
Moderate 65.9 Moderate 60.5
Cirrhosis 43.1 Cirrhosis 31.5
Upper 95% CI around incremental
SVR rates*
Mild 95.2 11,995 Mild 90.6 9,270
Moderate 84.2 Moderate 83.5
Cirrhosis 99.8 Cirrhosis 63.0
Annual transition probabilities†
Mild ﬁbrosis to moderate ﬁbrosis 0.025; 0.066 21,049; 17,480 0.025; 0.066 15,620; 14,202
Moderate ﬁbrosis to compensated
cirrhosis
0.010; 0.200 38,918; 12,686 0.010; 0.200 30,394; 9,430
Compensated cirrhosis to
decompensated cirrhosis
0.016; 0.085 23,716; 14,762 0.016; 0.085 20,185; 9,955
Compensated and decompensated
cirrhosis to HCC
0.010; 0.083 20,092; 13,551 0.010; 0.083 15,853; 8,919
Decompensated cirrhosis to liver
transplant
0.020; 0.033 19,579 0.020; 0.033 15,374
HCC to liver transplant 0; 0.132 19,775; 19,112 0; 0.132 15,588; 14,726
Decompensated cirrhosis to death 0.129; 0.750 20,799 0.129; 0.750 17,359
HCC to death 0.200; 0.860 18,953; 19,827 0.200; 0.860 14,509; 15,672
Liver transplant (ﬁrst year) to death 0.080; 0.210 19,280; 19,291 0.080; 0.210 14,934; 14,994
Liver transplant (subsequent years) to
death
0.022; 0.057 19,299 0.022; 0.057 15,032
Patients with cirrhosis who achieve an
SVR can progress to decompensated
cirrhosis‡
0; 0.0125 19,969 0; 0.0125 16,841
Utility in ﬁrst year of the model is the
same for both treatment arms§
19,633 14,778
Costs of telaprevir-induced adverse
events is triple
19,561 15,193
Age- and sex-standardized all-cause
mortality rates higher than those in
the general population
2.34 times the
rates reported
in Australian
life tables
26,115 2.34 times the rates reported in
Australian life tables
21,463
Discount rate (%) 0; 3.5 1,319; 12,522 0; 3.5 Dominates;
9,227
Time horizon (y) 30; 50 25,005; 19,316 30; 50 18,730; 14,959
Multivariate analyses
All transition probabilities based on
lowest values in the published
literature
44,250 34,589
All transition probabilities based on
highest values in the published
literature
8,121 6,430
All transition probabilities taken from
the Kirby Institute model [16]
15,125 12,083
Utility values taken from the Kirby
Institute model [16]
21,244 15,260
Markov state costs taken from the
Kirby Institute model [16]
19,204 14,964
Markov state costs, utilities, and
transition probabilities taken from
the Kirby Institute model [16]
17,239 12,613
continued on next page
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Table 6 – continued
Variable Treatment naive Treatment experienced
Values used in sensitivity
analysis
ICER
($)
Values used in sensitivity
analysis
ICER ($)
Markov health state costs are zero 28,243 25,535
Markov state Utility value Markov
state
Utility value
SVR states have same utility values as
non-SVR states (i.e., there is no utility
gain associated with achieving SVR)
SVR at mild stage 0.77 29,836 SVR at mild
stage
0.77 24,159
SVR at
moderate
stage
0.66SVR at moderate
stage
0.66
SVR at cirrhotic
stage
0.55 SVR at
cirrhotic
stage
0.55
CI, conﬁdence interval; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SVR,
sustained virological response.
* SVR rates for PR alone are unchanged (as per Table 1). The lower and upper 95% CI around the incremental SVR rate has been used to
estimate the SVR rate for the telaprevir plus PR group.
† The range used in the sensitivity analysis is based on the lowest and highest values in the published literature.
‡ Patients with cirrhosis who achieve an SVR can progress to decompensated cirrhosis with an annual probability of 0.0125 (based on odds
ratio from Brady et al. [20]).
§ In the treatment-naive setting (treatment-experienced setting), patients in both arms of the model have a utility weight of 0.782 (0.710)
during the ﬁrst year.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 9 2 – 8 0 0 799Furthermore, in one of these evaluations [5], telaprevir treatment
was restricted to patients with mild or moderate disease (i.e.,
patients with cirrhosis were not eligible for treatment). Even
though our study differs from these previous evaluations
(through the incorporation of the revised categorization of SVR
and Australian-speciﬁc stopping rules), the results of this study
emulate the economic analyses of telaprevir plus PR from other
countries [5–7], which conclude that telaprevir (and other pro-
tease inhibitors) are cost-effective treatments for patients with
genotype 1 chronic HCV infection.
Our telaprevir model includes three Markov health states to
depict the level of ﬁbrosis at baseline (mild ﬁbrosis, moderate
ﬁbrosis, and compensated cirrhosis). Of the four previous evalu-
ations of telaprevir, two similarly categorized ﬁbrosis into these
three states [5,7], whereas Liu et al. [8] used ﬁve states (F0, F1, F2,
F3, and cirrhosis), as did the Australian budget impact model
conducted by the Kirby Institute [16]. The fourth telaprevir study
by Camma et al. [6] categorized all precirrhotic patients into one
Markov state: chronic HCV [6]. Even though Liu et al. [8] and the
Australian Kirby Institute [16] apportioned ﬁbrosis into ﬁve
Markov states, utility weights in these analyses were either 1)
grouped into mild, moderate, and cirrhosis as per our analysis [8]
or b) identical for all precirrhotic Markov states (i.e., F0–F3) [16]. In
addition, in both studies, the annual costs of care applied were
identical across all precirrhotic Markov states. Furthermore, as
discussed above, the validation performed by the authors dem-
onstrates that the three-state ﬁbrosis model is consistent with
the Australian Kirby Institute model [16] at predicting down-
stream incidences. Therefore, it appears that the choice of a
three-state ﬁbrosis model does not substantially alter the over-
riding interpretation of the analysis.
In many other models [21–23], patients achieving an SVR have
the same annual rate of disease progression irrespective of
whether they had mild, moderate, or cirrhotic disease before
commencing treatment (i.e., patients achieving an SVR were
considered to be cured of their virus irrespective of their ﬁbrosis
status before treatment). Our model, however, conservativelyassumes that patients with cirrhosis achieving an SVR experience
disease progression to HCC (albeit at a slower rate than do those
who do not achieve an SVR).
This study has several limitations. First, this study was
conducted from an Australian health care system perspective.
Thus, the analysis does not include indirect costs, such as
absenteeism from work or the loss of productivity to employers.
The omission of indirect costs is likely to underestimate the
economic beneﬁts of telaprevir. Second, the modeled cohort does
not include patients with HCV infection who are coinfected with
HIV because these patients were not included in the telaprevir
randomized controlled trials. These patients are not excluded
from reimbursement in Australia. In addition, Markov transition
probabilities were assumed to be constant over time. Third,
Australian-speciﬁc utility weights are not available; therefore,
utility weights obtained from studies conducted in other coun-
tries were used. Finally, the full extent of the uncertainty
surrounding the cost-effectiveness of telaprevir in Australia
remains unknown because a probabilistic sensitivity analysis is
not required for reimbursement in Australia. As requested in the
guidelines for preparing submissions to the Pharmaceutical
Beneﬁts Advisory Committee [38], univariate and multivariate
sensitivity analyses were conducted.
In conclusion, the Markov model demonstrated that the
combination of telaprevir plus PR is cost-effective when com-
pared with PR alone in previously untreated and treated patients
with genotype 1 chronic HCV infection.
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